tirzepatide dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review | European Journal of Clinical Pharmacology Tirzepatide | DirectMeds
Description
Zepbound is approved for chronic weight management
Gastrointestinal effects were common after drug commencement or dose escalation in keeping with reports of tirzepatide in type 2 diabetes and obesity without diabetes (14,15)
For detailed information about managing these transitions, our guide on tirzepatide side effects covers what to expect and how to handle it
Meet Dr
Systematic review registration: identifier CRD42023412400
